29 Nov 2017 07:00
VECTURA GROUP PLC (the "Company")
Vectura Group appoints Juliet Thompson to its Board of Directors
Chippenham, UK - 29 November 2017: Vectura Group plc (LSE: VEC) ("Vectura", "the Group", "the Company"), an industry leading device and formulation business for inhaled airways products, is pleased to announce the appointment of Juliet Thompson as an Independent Non-Executive Director of the Company with effect from 1 December 2017. Upon appointment, Juliet will also become a member of the Audit Committee.
Juliet has spent approximately 20 years working as an investment banker and strategic advisor to healthcare companies in Europe. She has a strong track record of advising companies on corporate strategy across numerous transactions. She is a member of the Institute of Chartered Accountants in England and Wales (ACA) and holds a BSc degree in Economics from the University of Bristol. Her experience includes senior roles (Managing Director, Head of Corporate Finance and Partner) at Stifel Financial Corp, Nomura Code Securities and WestLB Panmure. She also worked at ICI PLC, Deloitte and Touche and HM Treasury.
She is currently a Non-Executive Director of Nexstim plc, a Nasdaq-listed Finnish medical technology company, Novacyt S.A., a French-based company whose shares are admitted to trade on AIM, and GI Dynamics, Inc a US headquartered, Australian stock exchange listed company. Juliet chairs the Audit Committee of each of these three companies. She is also Non-Executive Chair of the Board of Premier Veterinary Group plc, an LSE-listed company.
Bruno Angelici, Chairman of Vectura:
"I am delighted to welcome Juliet to Vectura. Her extensive experience both of the banking and industry will bring important insight to Board discussions, as well as supplementing and strengthening the existing skills and experience of the Board. We look forward to working with her."
In accordance with Listing Rule 9.6.13 (1) to (6), Juliet was a director of Big Rib Charters LLP, a family company, which went into voluntary strike off on 24 March 2015. There are no additional details to disclose under Listing Rule 9.6.13 (1) to (6) in respect of the appointment of Juliet Thompson.
Ends
Enquiries
Vectura Group plc | +44 (0)20 7881 0524 |
John Murphy Company Secretary | |
Bruno Angelici Chairman | |
Consilium Strategic Communications | +44 (0)20 3709 5700 |
Mary-Jane Elliott / Chris Welsh/ Jessica Hodgson/ |
About Vectura
Vectura, listed on the London Stock Exchange (LSE: VEC), is an industry leading device and formulation business for inhaled airways products offering a uniquely integrated inhaled drug delivery platform. With our extensive range of device and formulation technologies, integrated capabilities and collaborations, we are a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases.
Vectura has eight inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a portfolio of drugs in clinical development, a number of which have licence agreements with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Bayer, Chiesi, Almirall, Janssen, and Tianjin KingYork. For further information, please visit Vectura's website at www.vectura.com.